Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PYC-001 in Autosomal Dominant Optic Atrophy
NCT06970106Phase 2Recruiting
- Sponsor
- PYC Therapeutics
- Start
- Sep 2025
- Primary completion
- Oct 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of PYC-001 in autosomal dominant optic atrophy (ADOA), sponsored by PYC Therapeutics. Started Sep 2025; status: recruiting.
02
Drugs
PYC-001
03
Conditions
autosomal dominant optic atrophy (ADOA)
Beyond the preview
Go deeper on NCT06970106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970106.